PMID- 24338468
OWN - NLM
STAT- MEDLINE
DCOM- 20140327
LR  - 20191027
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 23
DP  - 2013 Dec
TI  - Intermittent versus every-day mesalazine therapy in preventing complications of 
      diverticular disease: a long-term follow-up study.
PG  - 3244-8
LID - 6112 [pii]
AB  - BACKGROUND: Mesalazine seems to be effective in preventing recurrence of acute 
      uncomplicated diverticulitis (AUD), but the optimal mesalazine scheme to achieve 
      these results is still debated. AIM: To assess the effectiveness of two different 
      mesalazine-based treatments in preventing recurrence of AUD and the occurrence of 
      other complications of diverticular disease (DD) during a long-term follow-up. 
      PATIENTS AND METHODS: We reviewed 311 patients suffer from recent episode of AUD 
      and undergoing to mesalazine treatment: 207 (group A, 105 males, median age 63 
      years, range 47-74 years) were treated with mesalazine 1.6 g for 10 days each 
      month, whilst 104 (group B, 55 males, median age 65 years, range 50-72 years) 
      were treated with mesalazine 1.6 g every day. Patients were followed-up every 6 
      months (median 7.5 months, range 5-13 months). RESULTS: Patients were followed-up 
      for a mean time of 3 years (range 12-72 months). Overall, occurrence of 
      complication recurred more frequently in group A than in group B (p = 0.030, 
      log-rank test). Acute diverticulitis recurred in 17 (8.2%) patients in group A 
      and in 3 (2.9%) in group B; diverticular bleeding occurred in 4 (1.9%) patients 
      in group A and in 1 (0.96%) patient in group B; surgery was required in 3 (1.4%) 
      patients in group A and in no (0%) patient in group B. CONCLUSIONS: This is the 
      first study showing that long-term mesalazine treatment is significantly better 
      that intermittent mesalazine treatment in preventing occurrence of DD 
      complications after an attack of acute diverticulitis.
FAU - Tursi, A
AU  - Tursi A
AD  - Gastroenterology Service, ASL BAT, Andria (Barletta), Italy. 
      antotursi@tiscali.it.
FAU - Di Mario, F
AU  - Di Mario F
FAU - Brandimarte, G
AU  - Brandimarte G
FAU - Elisei, W
AU  - Elisei W
FAU - Picchio, M
AU  - Picchio M
FAU - Loperfido, S
AU  - Loperfido S
FAU - Dal Bo', N
AU  - Dal Bo' N
FAU - Ferrara, F
AU  - Ferrara F
FAU - Marcello, R
AU  - Marcello R
FAU - Heras Salvat, H
AU  - Heras Salvat H
FAU - Scarpignato, C
AU  - Scarpignato C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Gastrointestinal Agents)
RN  - 4Q81I59GXC (Mesalamine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Chi-Square Distribution
MH  - Diverticulitis, Colonic/diagnosis/etiology/*prevention & control
MH  - Diverticulosis, Colonic/complications/diagnosis/*drug therapy
MH  - Diverticulum, Colon/complications/diagnosis/*drug therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Agents/*administration & dosage/adverse effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Mesalamine/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Secondary Prevention
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2013/12/18 06:00
MHDA- 2014/03/29 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/03/29 06:00 [medline]
AID - 6112 [pii]
AID - 10.1016/s0016-5085(13)62897-8 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 Dec;17(23):3244-8. doi: 
      10.1016/s0016-5085(13)62897-8.